SLX-300

SLX-300 is a preclinical-stage small molecule candidate being developed by Solaxa for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). It is characterized as a novel aminopyridine derivative that functions as an ion-channel modulator. The drug is designed to address the nerve damage and associated pain resulting from chemotherapy by targeting specific ion channels involved in neuronal signaling. While the exact ion channel subtype has not been publicly disclosed, the aminopyridine class is traditionally associated with potassium channel modulation. SLX-300 represents a targeted approach to mitigating the debilitating side effects of cancer treatment that currently lack effective therapeutic options.